Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.”In the company’s words, NCT07584967 on ClinicalTrials.gov
Other drugs for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Balcinrenone/dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv mecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up1
- 30 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07584967
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jul 2028 | A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure | |
| Phase 1/2Completed | 27 Oct 2025 | Phase Ib/IIa Trial With AC01 in Patients With HFrEF |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026